Improvement of non-alcoholic fatty liver disease treatment

Improvement of non-alcoholic fatty liver disease treatment

Aim of investigation. To estimate efficacy of combined hepatotropic drug «Hepaguard Active» for prevention of progression of non-alcoholic fatty liver disease (NAFLD) at steatosis stage.Material and methods. Overall 25 patients with verified NAFLD at steatosis stage were studied. All patients receiv...

Full description

Saved in:
Bibliographic Details
Main Authors: P. I. Seliverstov, V. G. Radchenko
Format: Article
Language:Russian
Published: Gastro LLC 2014-10-01
Series:Российский журнал гастроэнтерологии, гепатологии, колопроктологии
Subjects:
non-alcoholic fatty liver disease
steatosis
hepaguard active
Online Access:https://www.gastro-j.ru/jour/article/view/1127
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items